Stop-Loss Insurance Claims Surge Well Beyond Historical Norms in 2025
If your organization sponsors a self-insured health plan, the latest data from Tokio Marine HCC carries an urgent message: the cost pressures driving stop-loss insurance premiums higher are not letting up. In fact, they are accelerating. According to the company's newly released 2025 stop-loss experience analysis, specific stop-loss claims — those tied to individual patients with extremely high medical bills — came in 9.5 percentage points above the historical average recorded between 2019 and 2023. That compares with a 5-percentage-point overage reported in 2024, making 2025 a notably worse year by almost any measure.
"We were undeniably surprised by these trends," analysts from Tokio Marine HCC wrote in the report. The candor of that statement alone signals how dramatically the market has shifted, even for sophisticated underwriters who monitor healthcare utilization data around the clock.
Understanding Stop-Loss Insurance and Why It Matters to Employers
To appreciate the significance of these findings, it helps to understand what stop-loss insurance is and who relies on it. Approximately two-thirds of U.S. employers that offer health benefits now operate self-insured health plans rather than purchasing fully insured group coverage from a carrier. In a self-insured arrangement, the employer assumes direct financial responsibility for paying employee medical claims out of its own funds. This approach offers flexibility, cost transparency, and the potential for meaningful savings when a workforce stays healthy.
The risk, of course, is catastrophic exposure. A single employee diagnosed with cancer, requiring an organ transplant, or born with a rare genetic condition can generate millions of dollars in claims in a single plan year. Stop-loss insurance acts as a financial backstop. When an individual claimant's costs exceed a pre-set threshold — called the specific deductible — the stop-loss carrier reimburses the employer for spending above that line. Without this coverage, a handful of high-cost cases could devastate an employer's reserves and threaten the long-term viability of the self-funded plan itself.
What the 2025 Data Reveals About Specific Claims
The Tokio Marine HCC analysis focuses specifically on the "specific" layer of stop-loss protection, which covers individual high-cost claimants rather than aggregate plan-wide losses. The 9.5-percentage-point excess trend over the 2019–2023 baseline is a striking figure for several reasons.
- It accelerated from 2024. Last year's 5-percentage-point excess trend was already alarming to many in the industry. Seeing that figure nearly double in a single year suggests the drivers of high-cost claims are intensifying rather than normalizing.
- Analysts were caught off guard. Tokio Marine HCC's admission that the trends were "undeniably surprising" is significant. These are professionals whose entire business depends on accurately forecasting claim costs. When they express surprise, plan sponsors and brokers should pay close attention.
- The market has not yet fully adjusted. The report notes that while the stop-loss market has begun reacting to the changed environment, pricing has not yet reached levels adequate to absorb the ongoing trend. That means further tightening — in the form of higher premiums, stricter underwriting, or both — is likely ahead.
The Post-COVID Catch-Up Effect and Beyond
The roots of the current surge are not entirely mysterious. The COVID-19 pandemic profoundly disrupted normal patterns of healthcare utilization from 2020 through roughly 2023. Elective procedures were postponed, routine screenings were skipped, and many patients avoided in-person care altogether out of fear or necessity. The predictable result was a significant backlog of undiagnosed and untreated conditions.
By mid-2024, major carriers including Cigna and Sun Life Financial were already sounding the alarm about a sharp rebound in claims activity. What began as a post-pandemic catch-up wave appears to have morphed into something more durable — a sustained elevation in the severity and frequency of catastrophic individual claims that is proving harder to predict and price than most market participants had anticipated.
Adding complexity to the picture is the rapid adoption of high-cost specialty drugs, including GLP-1 medications for obesity and diabetes, as well as a growing pipeline of gene therapies and other advanced treatments that carry seven-figure price tags for a single course of care. These therapies are life-changing for patients, but they place enormous pressure on stop-loss carriers trying to set premiums that reflect true future risk.
What This Means for 2026 and 2027 Renewals
For employers currently navigating stop-loss renewals, the practical implications are significant. Tokio Marine HCC's analysis suggests that quotes for 2027 renewals could come in at levels comparable to those seen for 2026 — which were already elevated by historical standards. In other words, plan sponsors should not expect relief in the near term.
Brokers and benefits consultants are advising self-funded employers to take several proactive steps as they prepare for upcoming renewal cycles.
- Review specific deductible levels carefully. As premiums rise, some employers are tempted to raise their specific deductibles to control costs. While this can reduce premium outlay, it also increases direct exposure and may not be the right move for every organization's risk tolerance and cash flow position.
- Invest in population health management. Programs that identify high-risk employees early, improve medication adherence, and connect members with appropriate care can meaningfully reduce the likelihood of catastrophic claims developing in the first place.
- Evaluate specialty drug carve-outs and point solutions. Some stop-loss arrangements now allow employers to carve out certain high-cost therapies or work with specialized vendors to manage oncology, rare disease, and specialty pharmacy spend more aggressively.
- Engage your stop-loss carrier as a partner. Carriers increasingly offer data analytics, case management support, and clinical consultation services. Employers who use these resources tend to be better positioned to control costs and demonstrate favorable risk profiles at renewal.
The Broader Market Outlook
The Tokio Marine HCC report is the latest in a series of signals that the self-insured market is entering a period of sustained adjustment. Voya Financial, for example, raised employer stop-loss rates by an average of 24% in recent renewal cycles, a figure that reflects the same underlying trend dynamics documented in the Tokio Marine HCC analysis.
For employers, the takeaway is clear: budgeting for stop-loss cost increases in the range of 10% to 20% or more is increasingly prudent, and organizations that have not stress-tested their self-funded plans against catastrophic claim scenarios should do so before their next renewal. The window to act proactively is narrowing as the market continues to tighten.
Key Takeaways for Self-Funded Employers
The 2025 stop-loss experience data from Tokio Marine HCC reinforces what many benefits professionals have been warning about for over a year: the era of relatively predictable, moderate stop-loss cost increases has given way to a more volatile and expensive environment. Specific claim trends running nearly 10 percentage points above historical norms represent a serious financial planning challenge for any organization sponsoring a self-insured health plan.
Understanding the forces driving these trends — post-pandemic utilization rebounds, specialty drug costs, and the emergence of high-cost advanced therapies — can help employers make smarter decisions about plan design, vendor selection, and risk tolerance. Working closely with experienced benefits advisors and stop-loss carriers who offer robust analytics and clinical support will be essential for navigating the years ahead. The data is clear: now is not the time to adopt a wait-and-see approach.